Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5187022 | 0.81 | MTNR1A (0.45) | LMNASMN1; SMN2CYP1A2TP53GAA | |
| SCHEMBL5252893 | 0.80 | PTGES (0.54) | PTGESSMN1; SMN2KMT2A | |
| SCHEMBL5187917 | 0.78 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2CYP1A2TP53GAA | |
| SCHEMBL4142631 | 0.78 | CYP1A2 (0.73) | PTGESLMNASMN1; SMN2CYP1A2TP53 | |
| SCHEMBL5185693 | 0.76 | ALDH1A1 (0.41) | LMNASMN1; SMN2CYP1A2TP53GAA | |
| SCHEMBL12251014 | 0.75 | PTGES (0.55) | PTGESLMNASMN1; SMN2CYP1A2TP53 | |
| SCHEMBL5185323 | 0.74 | L3MBTL1 (0.41) | SMN1; SMN2CYP1A2TP53KMT2A | |
| SCHEMBL21228674 | 0.72 | NPC1 (0.56) | PTGESLMNASMN1; SMN2CYP1A2TP53 | |
| SCHEMBL4142636 | 0.71 | SMN1; SMN2 (0.71) | PTGESLMNASMN1; SMN2CYP1A2TP53 | |
| SCHEMBL10666333 | 0.71 | NPSR1 (0.57) | PTGESLMNASMN1; SMN2CYP1A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288549-B2 | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | AVENTIS PHARMA S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | PTGES 685/4885LMNA 2806/4885SMN1; SMN2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.